Memphasys (ASX:MEM) has signed a five-year commercial supply agreement with Centro Fertilita Assistita Italia, one of Italy's largest private IVF groups based in Naples.
Mayne Pharma Group (ASX:MYX) reported total net revenues of $165 million, a 5.5% decrease compared to the prior corresponding period.
Wesfarmers (ASX:WES) has placed more than 50 Priceline pharmacies operated by its largest franchisee, Infinity Pharmacy Group, into receivership.
Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has raised $5 million through a strongly supported placement.
Orthocell (ASX:OCC) has reached a key milestone in its US expansion, achieving 100 unit sales of its flagship nerve repair product, Remplir.
Lumos Diagnostics (ASX:LDX) entered into a new distribution agreement with the Interlux Group to commercialise its FebriDx test across the Baltic region.
TrivarX (ASX:TRI) has reported positive results from its clinical trial evaluating its single-lead ECG algorithm for screening current major depressive episodes in veterans.
Healthscope has confirmed full compliance with its lease obligations, having paid the December rent in full.
Anatara Lifesciences (ASX:ANR), a developer of evidence-based health products, has provided an update on its Anti-Obesity Project.
Neurotech International (ASX: NTI) received binding commitments from investors for approximately $4 million.
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute.
Proteomics International Laboratories (ASX:PIQ) has been granted a US patent for its proprietary blood test, PromarkerEso.
